JP2004533991A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004533991A5 JP2004533991A5 JP2002558387A JP2002558387A JP2004533991A5 JP 2004533991 A5 JP2004533991 A5 JP 2004533991A5 JP 2002558387 A JP2002558387 A JP 2002558387A JP 2002558387 A JP2002558387 A JP 2002558387A JP 2004533991 A5 JP2004533991 A5 JP 2004533991A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- hcv
- peptide
- epitope
- cell line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 34
- 210000004027 cell Anatomy 0.000 claims 17
- 239000003795 chemical substances by application Substances 0.000 claims 17
- 150000001413 amino acids Chemical class 0.000 claims 16
- 241000711549 Hepacivirus C Species 0.000 claims 15
- 238000000034 method Methods 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 10
- 101710125507 Integrase/recombinase Proteins 0.000 claims 8
- 229960005486 vaccine Drugs 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 102000007079 Peptide Fragments Human genes 0.000 claims 4
- 108010033276 Peptide Fragments Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 210000001124 body fluid Anatomy 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 108700008783 Hepatitis C virus E1 Proteins 0.000 claims 3
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000010839 body fluid Substances 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 102100027221 CD81 antigen Human genes 0.000 claims 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 150000001875 compounds Chemical group 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- SHFKGANKURXVMY-LCWPZEQJSA-N hcv e2 protein Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)CC1=CC=CC=C1 SHFKGANKURXVMY-LCWPZEQJSA-N 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 150000002484 inorganic compounds Chemical group 0.000 claims 1
- 229910010272 inorganic material Inorganic materials 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 150000002894 organic compounds Chemical group 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/728,720 US7091324B2 (en) | 1998-11-05 | 2000-12-01 | Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes |
| PCT/US2001/045029 WO2002057314A2 (en) | 2000-12-01 | 2001-11-30 | Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004533991A JP2004533991A (ja) | 2004-11-11 |
| JP2004533991A5 true JP2004533991A5 (enExample) | 2005-12-22 |
Family
ID=24928023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002558387A Pending JP2004533991A (ja) | 2000-12-01 | 2001-11-30 | コンホメーションエピトープを利用するｈｃｖ感染の予防及び治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7091324B2 (enExample) |
| EP (1) | EP1409682A2 (enExample) |
| JP (1) | JP2004533991A (enExample) |
| AU (1) | AU2002246545A1 (enExample) |
| CA (1) | CA2437082A1 (enExample) |
| WO (1) | WO2002057314A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060188511A1 (en) * | 1998-11-05 | 2006-08-24 | Foung Steven K | Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes |
| IL137522A (en) * | 2000-07-26 | 2007-06-17 | Drk Blutspendediendst Baden Wu | HCV human monoclonal antibody E2 glycoprotein antibody |
| DE60231475D1 (de) | 2001-01-12 | 2009-04-23 | Molecules Of Man Ab | Materialien und methoden zur behandlung von hepatitis c |
| US7326536B2 (en) * | 2001-05-03 | 2008-02-05 | Eli Lilly And Company | Agents for treatment of HCV and methods of use |
| ITRM20020049A1 (it) * | 2002-01-30 | 2003-07-30 | Biostrands S R L | Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. |
| FR2850384A1 (fr) * | 2003-01-28 | 2004-07-30 | Centre Nat Rech Scient | Antigenes mimant les domaines extracellulaires de proteines membranaires de type iii issues de microorganismes intracellulaires pathogenes, anticorps conformationnels derives, et leurs applications |
| EP2336176B1 (en) | 2003-04-01 | 2015-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies directed against hepatitis c virus e1e2 complex, and their epitopes |
| WO2006039326A2 (en) * | 2004-09-29 | 2006-04-13 | The Administrators Of The Tulane Educational Fund | Inhibitors of hepatitits c virus |
| EP1669368A1 (en) * | 2004-12-13 | 2006-06-14 | Genoscience | Use of peptides from the E2 protein of HCV for treating HCV infection |
| MY170607A (en) | 2006-09-07 | 2019-08-20 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| US7858752B2 (en) | 2006-12-05 | 2010-12-28 | Abbott Laboratories | Recombinant antibodies against hepatitis C virus and methods of obtaining and using same |
| JP2012504602A (ja) | 2008-10-05 | 2012-02-23 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | Ｃ型肝炎抗体およびその使用 |
| WO2010148117A1 (en) | 2009-06-17 | 2010-12-23 | Scantibodies Laboratory, Inc. | Therapeutic and diagnostic affinity purified specific polyclonal antibodies |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4415491A (en) | 1980-01-14 | 1983-11-15 | The Regents Of The University Of California | Synthetic vaccine peptide epitomes of hepatitis B surface antigen |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4683136A (en) | 1985-03-06 | 1987-07-28 | Scripps Clinic And Research Foundation | Proteinaceous antigens with conformation-independent and conformation-dependent determinants |
| IL86832A (en) | 1987-06-22 | 2002-09-12 | Medeva Holdings Bv | A recombinant DNA molecule containing a nucleotide sequence of part of the region encoding HBV pre-1s, an immunogenic particle containing multiple peptide monomers containing a pre-s1 epitope and pharmaceutical preparations containing it |
| US5350671A (en) | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
| US6027729A (en) | 1989-04-20 | 2000-02-22 | Chiron Corporation | NANBV Diagnostics and vaccines |
| US5308750A (en) * | 1989-12-22 | 1994-05-03 | Abbott Laboratories | Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same |
| US5106726A (en) | 1990-02-16 | 1992-04-21 | United Biomedical, Inc. | Synthetic peptides specific for the detection of antibodies to HCV |
| KR100217483B1 (ko) | 1990-04-06 | 1999-09-01 | 프랭크 쿵 | C형 간염 바이러스 에피토프 |
| US6274148B1 (en) | 1990-11-08 | 2001-08-14 | Chiron Corporation | Hepatitis C virus asialoglycoproteins |
| EP0491077A1 (en) | 1990-12-19 | 1992-06-24 | Medeva Holdings B.V. | A composition used as a therapeutic agent against chronic viral hepatic diseases |
| US5574132A (en) | 1991-04-05 | 1996-11-12 | Biochem Immunosystems Inc. | Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV) |
| WO1993006126A1 (en) | 1991-09-13 | 1993-04-01 | Chiron Corporation | Immunoreactive hepatitis c virus polypeptide compositions |
| US5514539A (en) | 1993-06-29 | 1996-05-07 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines |
| US5709995A (en) | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
| JPH07299655A (ja) | 1994-04-30 | 1995-11-14 | Aisin Seiki Co Ltd | 内スプライン歯面仕上機 |
| PT773957E (pt) | 1994-07-29 | 2005-11-30 | Chiron Corp | Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos |
| US5985609A (en) | 1994-11-04 | 1999-11-16 | Mogam Biotechnology Research Institute | Process for preparing hepatitis C virus envelope glycoproteins |
| US6020122A (en) | 1995-06-07 | 2000-02-01 | Abbott Laboratories | Hepatitis C virus second envelope (HCV-E2) glycoprotein expression system |
| US6538114B1 (en) * | 1996-04-19 | 2003-03-25 | Karolina Innovations Ab | Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen |
| US6747136B2 (en) * | 1996-04-19 | 2004-06-08 | Karolinska Innovations Ab | Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen |
| DE69836758T2 (de) | 1997-11-06 | 2007-10-11 | Innogenetics N.V. | Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv |
| US6951646B1 (en) * | 1998-07-21 | 2005-10-04 | Genmab A/S | Anti hepatitis C virus antibody and uses thereof |
| EP1127170A4 (en) | 1998-11-05 | 2005-04-27 | Univ Leland Stanford Junior | HUMAN MONOCLONAL ANTIBODIES OF THE HEPATITIS C VIRUS (HCV) PAN |
-
2000
- 2000-12-01 US US09/728,720 patent/US7091324B2/en not_active Expired - Fee Related
-
2001
- 2001-11-30 WO PCT/US2001/045029 patent/WO2002057314A2/en not_active Ceased
- 2001-11-30 CA CA002437082A patent/CA2437082A1/en not_active Abandoned
- 2001-11-30 EP EP01994118A patent/EP1409682A2/en not_active Ceased
- 2001-11-30 JP JP2002558387A patent/JP2004533991A/ja active Pending
- 2001-11-30 AU AU2002246545A patent/AU2002246545A1/en not_active Abandoned
-
2006
- 2006-08-15 US US11/504,974 patent/US20070032635A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6951646B1 (en) | Anti hepatitis C virus antibody and uses thereof | |
| TWI430810B (zh) | ＴＮＦα相關病症之治療 | |
| TWI307716B (en) | Dual specificity antibodies and methods of making and using | |
| CN111440229B (zh) | 新型冠状病毒t细胞表位及其应用 | |
| US20150023980A1 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| CN109311983B (zh) | 人源化抗clever-1抗体及其用途 | |
| JP2004533991A5 (enExample) | ||
| JP2004534513A5 (enExample) | ||
| JP2013538195A (ja) | Ｈｉｖ汚染の予防、ａｉｄｓを含むｈｉｖによって引き起こされる疾患及びｈｉｖに関連する疾患の予防及び治療のための医薬及び方法 | |
| JP2005531286A (ja) | ＨＣＶＥ２グリコプロテインに対して向けられ、ｉｎｖｉｔｒｏ中和活性を有するヒトモノクローナル抗体Ｆａｂ断片 | |
| KR20180084045A (ko) | 비형 간염 표면 항원에 대한 항체 및 그의 용도 | |
| JP2024149479A (ja) | 黄熱を処置するための方法および組成物 | |
| CN117603358B (zh) | 一种广谱新型冠状病毒的双特异性抗体 | |
| WO2022044573A1 (ja) | コロナウイルススパイク蛋白に対するヒト抗体またはその抗原結合断片 | |
| JP2006504645A5 (enExample) | ||
| JP2005538689A (ja) | ワクシニアまたは天然痘に対する治療のためのヒト抗体 | |
| JP2003502285A (ja) | Ｔｔウイルス配列由来のペプチドおよびｔｔウイルスに結合する単一特異性抗体 | |
| CN100588660C (zh) | Sars冠状病毒核衣壳蛋白的抗原决定簇及其应用 | |
| JPWO2022090353A5 (enExample) | ||
| CN111205364A (zh) | 抗hpv31l1的单克隆中和抗体及其应用 | |
| CN111732653B (zh) | Hpv52l1的单克隆中和抗体及其应用 | |
| CN111116740B (zh) | Hpv33l1的单克隆中和抗体及其应用 | |
| Liu | Natural and biotech‐derived therapeutic proteins: What is the future? | |
| WO2025166169A1 (en) | Compositions, doses, and methods for treatment of c1s mediated diseases and disorders | |
| Șerban et al. | SARS-CoV2 Infection in a Multiple Sclerosis Patient Treated with Natalizumab–A Case Presentation |